Diamedica Therapeutics Stock Analysis
| DMAC Stock | USD 3.82 0.25 7.00% |
DiaMedica Therapeutics is undervalued with Real Value of 4.92 and Target Price of 8.75. The main objective of DiaMedica Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what DiaMedica Therapeutics is worth, separate from its market price. There are two main types of DiaMedica Therapeutics' stock analysis: fundamental analysis and technical analysis.
The DiaMedica Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and DiaMedica Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
DiaMedica | Build AI portfolio with DiaMedica Stock |
DiaMedica Stock Analysis Notes
About 16.0% of the company shares are held by company insiders. The book value of DiaMedica Therapeutics was currently reported as 0.79. The company recorded a loss per share of 0.68. DiaMedica Therapeutics last dividend was issued on the 15th of November 2018. The entity had 1:20 split on the 15th of November 2018. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To learn more about DiaMedica Therapeutics call Dietrich MBA at 763 496 5454 or check out https://www.diamedica.com.DiaMedica Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. DiaMedica Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding DiaMedica Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| DiaMedica Therapeutics generated a negative expected return over the last 90 days | |
| DiaMedica Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: With percent ownership, DiaMedica Therapeutics Inc. insiders have a lot riding on the companys future |
DiaMedica Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DiaMedica Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
DiaMedica Largest EPS Surprises
Earnings surprises can significantly impact DiaMedica Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-08 | 2024-03-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2023-08-14 | 2023-06-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2020-08-11 | 2020-06-30 | -0.15 | -0.17 | -0.02 | 13 |
DiaMedica Therapeutics Environmental, Social, and Governance (ESG) Scores
DiaMedica Therapeutics' ESG score is a quantitative measure that evaluates DiaMedica Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of DiaMedica Therapeutics' operations that may have significant financial implications and affect DiaMedica Therapeutics' stock price as well as guide investors towards more socially responsible investments.
DiaMedica Therapeutics Thematic Classifications
In addition to having DiaMedica Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
DiaMedica Stock Institutional Investors
| Shares | Goldman Sachs Group Inc | 2025-03-31 | 121.8 K | Blackrock Inc | 2025-03-31 | 106.3 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 103.6 K | Jane Street Group Llc | 2025-03-31 | 100.7 K | State Street Corp | 2025-03-31 | 85 K | Ronald Blue Trust, Inc. | 2025-03-31 | 69.1 K | Hrt Financial Llc | 2025-03-31 | 56.7 K | Citadel Advisors Llc | 2025-03-31 | 53.7 K | Catalyst Financial Partners Llc | 2025-03-31 | 38.5 K | Cooperman Leon G | 2025-03-31 | 1.6 M | Vanguard Group Inc | 2025-03-31 | 1.4 M |
DiaMedica Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 163.81 M.DiaMedica Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.60) | (0.63) |
Management Efficiency
DiaMedica Therapeutics has return on total asset (ROA) of (0.4127) % which means that it has lost $0.4127 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6725) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of June 21, 2025, Return On Tangible Assets is expected to decline to -0.55. In addition to that, Return On Capital Employed is expected to decline to -0.68. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.4 M, whereas Other Assets are forecasted to decline to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.01 | 1.43 | |
| Tangible Book Value Per Share | 1.01 | 0.68 | |
| Enterprise Value Over EBITDA | (8.89) | (9.34) | |
| Price Book Value Ratio | 5.39 | 5.12 | |
| Enterprise Value Multiple | (8.89) | (9.34) | |
| Price Fair Value | 5.39 | 5.12 | |
| Enterprise Value | 195 M | 204.8 M |
Evaluating the management effectiveness of DiaMedica Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The DiaMedica Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 21st of June, DiaMedica Therapeutics shows the Mean Deviation of 3.21, coefficient of variation of (790.66), and Standard Deviation of 4.56. DiaMedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.DiaMedica Therapeutics Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Kaufman Adaptive Moving Average allows the user to define DiaMedica Therapeutics range across which they want the smoothing.
DiaMedica Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DiaMedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on DiaMedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DiaMedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DiaMedica Therapeutics Outstanding Bonds
DiaMedica Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DiaMedica Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DiaMedica bonds can be classified according to their maturity, which is the date when DiaMedica Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
DiaMedica Therapeutics Predictive Daily Indicators
DiaMedica Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of DiaMedica Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
DiaMedica Therapeutics Corporate Filings
F4 | 3rd of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 15th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 13th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 8th of April 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 28th of March 2025 Other Reports | ViewVerify | |
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
DiaMedica Therapeutics Forecast Models
DiaMedica Therapeutics' time-series forecasting models are one of many DiaMedica Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary DiaMedica Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About DiaMedica Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how DiaMedica Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DiaMedica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as DiaMedica Therapeutics. By using and applying DiaMedica Stock analysis, traders can create a robust methodology for identifying DiaMedica entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (10.18) | (10.69) | |
| Operating Profit Margin | (12.17) | (12.78) | |
| Net Loss | (10.32) | (10.84) |
Current DiaMedica Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. DiaMedica analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. DiaMedica analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 8.75 | Strong Buy | 4 | Odds |
Most DiaMedica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand DiaMedica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of DiaMedica Therapeutics, talking to its executives and customers, or listening to DiaMedica conference calls.
DiaMedica Stock Analysis Indicators
DiaMedica Therapeutics stock analysis indicators help investors evaluate how DiaMedica Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading DiaMedica Therapeutics shares will generate the highest return on investment. By understating and applying DiaMedica Therapeutics stock analysis, traders can identify DiaMedica Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 4.5 M | |
| Common Stock Shares Outstanding | 40.4 M | |
| Total Stockholder Equity | 40.7 M | |
| Tax Provision | 30 K | |
| Property Plant And Equipment Net | 427 K | |
| Cash And Short Term Investments | 44.1 M | |
| Cash | 3 M | |
| Accounts Payable | 940 K | |
| Net Debt | -2.7 M | |
| 50 Day M A | 3.9382 | |
| Total Current Liabilities | 5.4 M | |
| Non Current Assets Total | 1.7 M | |
| Non Currrent Assets Other | 1.3 M | |
| Stock Based Compensation | 2.1 M |
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |